ESMO 2025 preview – first clinical results
The ESMO regular abstract lift reveals first human datasets for several projects.
Incyte goes pivotal in CDK2
The Maestra-2 trial will test INCB123667 in platinum-resistant ovarian cancer.
ESMO 2025 preview – Astellas's third Claudin18.2 shot
Data with the T-cell engager ASP2138 look lukewarm, but could improve with combos.
Grit enters the in vivo Car-T race
And Vironexis’s second gene therapy-encoded T-cell engager will soon go clinical.
